Studying subtypes of bronchiectasis in adults to understand who may respond to treatment
Observes adults with bronchiectasis to find molecular subgroups linked to clinical outcomes.
Key facts
- Who runs it
- University of Dundee
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 1 Nov 2019
- Expected to end
- 1 Feb 2027
- Type of study
- Observational
- Record updated
- 22 March 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with bronchiectasis, a long-term widening of the airways, whose disease is currently stable. It is an observational study that looks for patient subgroups.
- Age
- 18 Years and older
- Sex
- All sexes can join
- Disease stage
- Bronchiectasis seen on a previous CT scan, with cough, sputum (phlegm) and/or repeated chest infections. A lung doctor must have made bronchiectasis the main diagnosis. Disease must have been stable for 4 weeks.
- Earlier treatment
- No antibiotics or corticosteroids for a lung flare-up in the previous 4 weeks.
Main reasons for not taking part
- Unable to give informed consent
- Younger than 18 years
- Active tuberculosis
- Antibiotics or corticosteroids for a lung flare-up in the previous 4 weeks
- Bronchiectasis caused by cystic fibrosis
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- A previous CT scan showing bronchiectasis along with compatible clinical syndrome of cough, sputum production and/or recurrent respiratory tract infections
- A primary diagnosis of bronchiectasis made by a respiratory physician
- At the screening visit the individual will have been clinically stable for 4 weeks indicated by the lack of any treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks
Who cannot take part
- Treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks
- Patients with active tuberculosis
- <18years of age
- Inability to give informed consent
- Bronchiectasis due to cystic fibrosis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Bronchiectasis is a complex heterogeneous disorder. Treatment is challenging and many recent randomized controlled trials have been negative. It is believed that bronchiectasis as a broad diagnosis incorporates multiple different patient subgroups (also known as phenotypes) and molecular entities (referred to as endotypes). This study aims to phenotype and endotype bronchiectasis during stable disease and exacerbations, to develop strategies for personalised medicine.
Read full original descriptionShow less
Primary Objective To determine molecular endotypes of bronchiectasis which can guide response to treatment.
Secondary Objectives
1. To determine molecular endotypes of stable bronchiectasis 2. To determine the causes and inflammatory profiles of bronchiectasis exacerbations 3. To validate candidate biomarkers of stable and exacerbation endotypes to use in stratified medicine 4. To perform in-vivo or in-vitro proof of concept studies using phenotypic data to identify patient populations likely to benefit in future randomized controlled trials
This is an observational cohort study that will aim to identify patient subgroups and link these with meaningful clinical outcomes.
The group in the trial
- Patients with bronchiectasis
Adult patients with bronchiectasis meeting the inclusion criteria.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping. An EMBARC2 and EMBARC3 Study
- Plain-language title
- Studying subtypes of bronchiectasis in adults to understand who may respond to treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Publications
- Record updated
- 22 March 2023